eigerbioadmin

Home»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 163 blog entries.
15 11, 2019

Eiger to Present at Jefferies 2019 London Healthcare Conference

2019-11-15T17:27:31+00:00

Eiger to Present at Jefferies 2019 London Healthcare Conference PALO ALTO, Calif. – November 15, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies 2019 London Healthcare Conference on November [...]

Eiger to Present at Jefferies 2019 London Healthcare Conference2019-11-15T17:27:31+00:00
12 11, 2019

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results

2019-11-12T21:55:21+00:00

Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 Median Decline of HDV RNA: -3.4 Log at Week 24 95% of Patients Achieve > [...]

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results2019-11-12T21:55:21+00:00
7 11, 2019

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

2019-11-07T21:42:42+00:00

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies Positive Phase 2 LIFT Lambda Combo Data as Late-Breaker at AASLD First-Ever Phase 3 HDV International D-LIVR Study Enrolling and Dosing Strong Balance Sheet with $109.9M in Cash & Investments PALO ALTO, [...]

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update2019-11-07T21:42:42+00:00
21 10, 2019

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019

2019-10-21T14:08:32+00:00

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019rectors >50% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24Median Decline of HDV RNA: -3.4 Log at Week 2495% of Patients Achieve >2 Log Decline in HDV [...]

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 20192019-10-21T14:08:32+00:00
28 09, 2019

Eiger to Present at Cantor 2019 Global Healthcare Conference

2019-09-28T15:38:30+00:00

Eiger to Present at Cantor 2019 Global Healthcare Conference PALO ALTO, Calif. – September 27, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Cantor 2019 Global Healthcare Conference on October [...]

Eiger to Present at Cantor 2019 Global Healthcare Conference2019-09-28T15:38:30+00:00
29 08, 2019

Eiger BioPharmaceuticals to Participate in September Conferences

2019-08-29T20:16:25+00:00

Eiger BioPharmaceuticals to Participate in September Conferences PALO ALTO, Calif. – August 29, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September: Baird 2019 Global Healthcare Conference at the [...]

Eiger BioPharmaceuticals to Participate in September Conferences2019-08-29T20:16:25+00:00
20 08, 2019

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection

2019-08-20T12:48:11+00:00

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection Fourth Eiger Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., August 20, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and [...]

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection2019-08-20T12:48:11+00:00
6 08, 2019

Eiger BioPharmaceuticals to Participate in Investor Conferences in August

2019-08-06T18:37:29+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences in August PALO ALTO, Calif. – August 5, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August. BTIG Biotechnology Conference at St. Regis [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences in August2019-08-06T18:37:29+00:00
17 06, 2019

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)

2019-06-17T20:57:19+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., June 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)2019-06-17T20:57:19+00:00
10 06, 2019

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs

2019-06-10T13:59:43+00:00

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PALO ALTO, Calif., June 10, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach, PhD, RPh as Vice President [...]

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs2019-06-10T13:59:43+00:00